Methods and compositions for positron emission tomography myocardial perfusion imaging
US-9789211-B2 · Oct 17, 2017 · US
US10646598B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10646598-B2 |
| Application number | US-201615194425-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 27, 2016 |
| Priority date | Jan 27, 2009 |
| Publication date | May 12, 2020 |
| Grant date | May 12, 2020 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.
Opening claim text (preview).
We claim: 1. A chemical composition comprising a molecule selected from the group consisting of wherein the molecule is complexed with a metal or metal ion. 2. The chemical composition according to claim 1 , wherein the metal is selected from the group consisting of 90 Y, Gd, 68 Ga, 57 Co, 60 Co, 52 Fe, 64 Cu and 67 Cu. 3. A bifunctional chelator and targeting moiety conjugate comprising a molecule selected from the group consisting of wherein the targeting moiety is selected from the group consisting of a peptide and an antibody. 4. The bifunctional chelator and targeting moiety conjugate according to claim 3 , wherein the peptide is selected from the group consisting of a RGD, Asp-Gly-Glu-Ala (DGEA), bombesin peptides (BBN), and uPAR peptides. 5. A method of positron emission tomography (PET) imaging comprising: introducing into a subject a chemical composition according to claim 2 ; and imaging the subject after introducing the composition.
conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title
specific for metastasis · CPC title
chelates from cyclic ligands, e.g. DOTA · CPC title
with the first amino acid being acidic · CPC title
Bridged systems · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.